

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

INCLUDED BY MSCI AS A CONSTITUENT OF THE MSCI GLOBAL SMALL CAP INDEXES – CHINA

The board of directors (the “**Board**”) of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred to as the “**Group**”) is pleased to announce that the Company has been included by Morgan Stanley Capital International (“**MSCI**”) as a constituent of the MSCI Global Small Cap Indexes – China, effective as of the close of 29 May 2015.

MSCI is a leading provider of global equity indexes and benchmark related products and services to investors worldwide. MSCI indexes are among the most widely used international equity benchmarks by institutional investors. Constituent stocks included in the index are companies with excellent performance and development potential.

The Board believes that the inclusion of the Company into such index demonstrates investors’ recognition of the Group’s performance in the capital market. It further enhances the corporate image of the Group and helps the Group’s development of its business in the biopharmaceutical industry.

By Order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 14 May 2015

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.